{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:51:18Z","timestamp":1785873078730,"version":"3.56.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32302955"],"award-info":[{"award-number":["32302955"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202206010063"],"award-info":[{"award-number":["202206010063"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bbrc.2026.153866","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:18:26Z","timestamp":1780589906000},"page":"153866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting the conserved RNA-dependent RNA polymerase with antisense oligonucleotides suppresses SARS-CoV-2 variants"],"prefix":"10.1016","volume":"828","author":[{"given":"Rui","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6650-7870","authenticated-orcid":false,"given":"Jia","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbrc.2026.153866_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.153866_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.834098","article-title":"SARS-CoV-2's variants of concern: a brief characterization","volume":"13","author":"Scovino","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153866_bib3","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","article-title":"Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion","volume":"15","author":"Planas","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153866_bib4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12985-024-02573-x","article-title":"Immune evasion after SARS-CoV-2 Omicron BA.5 and XBB.1.9 endemic observed from Guangdong Province, China from 2022 to 2023","volume":"21","author":"Zhang","year":"2024","journal-title":"Virol. J."},{"issue":"2","key":"10.1016\/j.bbrc.2026.153866_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/acsabm.3c00339","article-title":"Targeting RdRp of SARS-CoV-2 with De Novo Molecule Generation","volume":"7","author":"Vijay","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.bbrc.2026.153866_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131756","article-title":"RdRp (RNA-dependent RNA polymerase): a key target providing anti-virals for the management of various viral diseases","volume":"1250","author":"Pathania","year":"2022","journal-title":"J. Mol. Struct."},{"issue":"11","key":"10.1016\/j.bbrc.2026.153866_bib7","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bbrc.2026.153866_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102440","article-title":"Nucleic acid therapeutics: past, present, and future","volume":"36","author":"Naeem","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bbrc.2026.153866_bib9","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.2147\/DDDT.S282252","article-title":"Repurposing anti-cancer drugs for COVID-19 treatment","volume":"14","author":"Borcherding","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"issue":"10","key":"10.1016\/j.bbrc.2026.153866_bib10","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","article-title":"The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations","volume":"31","author":"Joyce","year":"2022","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bbrc.2026.153866_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coviro.2021.06.003","article-title":"Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19","volume":"50","author":"Painter","year":"2021","journal-title":"Curr. Opin. Virol."},{"issue":"5","key":"10.1016\/j.bbrc.2026.153866_bib12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.bbrc.2026.153866_bib13","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for High-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.bbrc.2026.153866_bib14","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bbrc.2026.153866_bib15","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/infdis\/jiad270","article-title":"Viral resistance analyses from the remdesivir phase 3 adaptive COVID-19 treatment Trial-1 (ACTT-1)","volume":"228","author":"Hedskog","year":"2023","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.bbrc.2026.153866_bib16","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1038\/s41467-021-26760-4","article-title":"Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets","volume":"12","author":"Cox","year":"2021","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.bbrc.2026.153866_bib17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S1473-3099(25)00238-5","article-title":"Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study","volume":"25","author":"Ogbuagu","year":"2025","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.bbrc.2026.153866_bib18","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1021\/acsomega.1c05998","article-title":"Potent inhibitory activities of the adenosine analogue cordycepin on SARS-CoV-2 replication","volume":"7","author":"Rabie","year":"2022","journal-title":"ACS Omega"},{"issue":"6","key":"10.1016\/j.bbrc.2026.153866_bib19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1021\/acsbiomedchemau.2c00039","article-title":"Forodesine and riboprine exhibit strong Anti-SARS-CoV-2 repurposing potential: in silico and in vitro studies","volume":"2","author":"Rabie","year":"2022","journal-title":"ACS Bio Med Chem Au"},{"issue":"46","key":"10.1016\/j.bbrc.2026.153866_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202201912","article-title":"A series of adenosine analogs as the first efficacious Anti-SARS-CoV-2 drugs against the B.1.1.529.4 lineage: a preclinical repurposing research study","volume":"7","author":"Rabie","year":"2022","journal-title":"ChemistrySelect"},{"issue":"4","key":"10.1016\/j.bbrc.2026.153866_bib21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12033-022-00551-8","article-title":"Potent dual polymerase\/exonuclease inhibitory activities of antioxidant aminothiadiazoles against the COVID-19 omicron virus: a promising in Silico\/In vitro repositioning research study","volume":"66","author":"Rabie","year":"2024","journal-title":"Mol. Biotechnol."},{"issue":"10","key":"10.1016\/j.bbrc.2026.153866_bib22","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.32604\/biocell.2023.030057","article-title":"Future of the current anticoronaviral agents: a viewpoint on the validation for the next COVIDs and pandemics","volume":"47","author":"Rabie","year":"2023","journal-title":"Biocell"},{"key":"10.1016\/j.bbrc.2026.153866_bib23","first-page":"53","article-title":"Minireview of progress in the structural study of SARS-CoV-2 proteins","volume":"1","author":"Zhu","year":"2020","journal-title":"Curr. Res. Microb. Sci."},{"issue":"6492","key":"10.1016\/j.bbrc.2026.153866_bib24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"issue":"7944","key":"10.1016\/j.bbrc.2026.153866_bib25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bbrc.2026.153866_bib26","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jaci.2024.06.007","article-title":"Human angiotensin-converting enzyme 2-specific antisense oligonucleotides reduce infection with SARS-CoV-2 variants","volume":"154","author":"Lu","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.bbrc.2026.153866_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281281","article-title":"Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection","volume":"18","author":"Qiao","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2026.153866_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2025.108454","article-title":"Targeting conserved regions of the SARS-CoV-2 polymerase (RdRp) with kinase inhibitors as an effective new tactic for discovering dual-action \"antiviral\u2013antiinflammatory\" drugs against COVID-19","volume":"119","author":"Rabie","year":"2025","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.153866_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100055","article-title":"Teriflunomide: a possible effective drug for the comprehensive treatment of COVID-19","volume":"2","author":"Rabie","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"issue":"9","key":"10.1016\/j.bbrc.2026.153866_bib30","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1016\/j.apsb.2024.05.008","article-title":"Current status and trends in small nucleic acid drug development: leading the future","volume":"14","author":"Miao","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbrc.2026.153866_bib31","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jconrel.2022.10.050","article-title":"Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics","volume":"352","author":"Ramasamy","year":"2022","journal-title":"J. Contr. Release"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26006303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26006303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:41:32Z","timestamp":1785872492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26006303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S0006291X26006303"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153866","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the conserved RNA-dependent RNA polymerase with antisense oligonucleotides suppresses SARS-CoV-2 variants","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153866","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"153866"}}